Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline


#288677

N/A

GBI Research

$ 4995

In Stock

Hypertension is a chronic medical condition characterized by elevated blood pressure in the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-Pacific (APAC) regions of China, India, Australia, and Japan. This high prevalence is a substantial contributor to healthcare costs and a major cause of morbidity. Despite this, awareness of hypertension is low among physicians, patients, and the public alike, leading to poor blood pressure control.

The classes of drugs prescribed to treat hypertension are Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor Blockers (ARB), Calcium Channel Blockers (CCB), beta-blockers, renin inhibitors, and diuretics. The percentage of patients treated using monotherapy and combination therapy (including fixed-dose combinations) varies from country to country. The most commonly prescribed drugs in the CCB class are amlodipine and lercanidipine, while the leading ARBs are telmisartan, candesartan, olmesartan, irbesartan, losartan, valsartan, azilsartan medoxomil, and eprosartan. Ramipril, imidapril, perindopril, enalapril, lisinopril, benazepril, fosinopril, trandolapril, and quinapril dominate the ACEIs.

Scope
  • Hypertension prevalence is a prominent contributor to market size in the assessed countries. The market is mostly dominated by generics, and there are only a few patented products.
  • Will generics continue to dominate treatment?
  • How do the elderly populations and their associated risk factors affect prevalence?
  • The current anti-hypertensive therapeutics pipeline is weak, comprising 124 molecules in various stages of development, dominated by small molecules.
  • Will the upcoming molecules change the treatment paradigm in the near future?
  • How will the weak pipeline affect the market?
  • Analysis of clinical trials since 2006 identified that anti-hypertensive products have a high rate of attrition.
  • How do failure rates vary by product stage of development, molecule type, and mechanism of action?
  • How do other factors such as average trial duration and trial size influence the costs and risks associated with product development?
  • Over the 2014–2021 forecast period, the APAC anti-hypertensive therapeutics market is expected to increase in value at a CAGR of 3.4% from $15.7 billion to just over 19.9 billion. Growth is projected to vary considerably across the four assessed markets.
  • Which markets make the most significant contribution to the current market size?
  • What are the epidemiology trends in these markets?
  • Will branded products’ patent expirations pose a significant threat?
  • Will new market entrants over the forecast period lead to substantial changes in annual therapy costs?
Reasons To Buy

This report will enable you to:
  • Understand the clinical context of hypertension by considering symptoms, etiology, pathophysiology, co-morbidities and complications, epidemiology, diagnosis, and treatment options.
  • Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape, and recognize gaps.
  • Appreciate key anti-hypertensive pipeline trends in molecule type, administration route, mechanism of action, and novelty.
  • Consider market opportunities and potential risks by examining trends in anti-hypertensive clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
  • Compare treatment usage patterns, annual therapy costs, and market growth projections for the China, India, Australia, and Japan.
  • Discover trends in licensing and co-development deals concerning anti-hypertensive products and identify the major strategic consolidations that have shaped the commercial landscape.
Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Pathophysiology
2.2 Etiology
2.3 Signs and Symptoms
2.4 Co-morbidities and Complications
2.5 Diagnosis
2.5.1 Office or Clinic Blood Pressure Monitoring
2.5.2 Ambulatory Blood Pressure Monitoring
2.5.3 Home Blood Pressure Monitoring
2.5.4 Miscellaneous Methods
2.5.5 Diagnosis of Target Organ Damage
2.5.6 Diagnosis of Hypertension in Pregnancy
2.6 Classification
2.7 Epidemiology
2.8 Prognosis
2.9 Treatment and Management
2.9.1 Treatment Strategy

3 Marketed Products
3.1 Key Marketed Products
3.1.1 Prestalia (perindopril arginine + amlodipine besylate)
3.1.2 Azilva (azilsartan medoxomil)
3.1.3 Amlodipine besylate
3.1.4 Telmisartan
3.1.5 Aliskiren
3.1.6 Olmesartan medoxomil
3.1.7 Valsartan
3.1.8 Losartan
3.1.9 Exforge (amlodipine + valsartan)
3.2 Heat Map for Marketed Products

4 Anti-hypertensive Market to 2021 – Pipeline Products
4.1 Overall Pipeline
4.1.1 Pipeline Analysis by Molecule Type
4.1.2 Pipeline Analysis by Mechanism of Action
4.2 Clinical Trial Analysis
4.2.1 Failure Rate
4.2.2 Clinical Trial Size
4.2.3 Duration
4.3 Promising Drug Candidates in Pipeline
4.3.1 SER-100
4.3.2 CS-3150

5 Market Forecast to 2021
5.1 Asia-Pacific Market
5.1.1 Treatment Use Patterns
5.1.2 Market Size
5.2 Australia
5.2.1 Treatment Use Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Size
5.3 India
5.3.1 Treatment Use Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 China
5.4.1 Treatment Use Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Size
5.5 Japan
5.5.1 Treatment Use Patterns
5.5.2 Annual Cost of Therapy
5.5.3 Market Size
5.6 Drivers and Barriers
5.6.1 Drivers
5.6.2 Barriers

6 Deals and Strategic Consolidations
6.1 Licensing Agreements
6.1.1 Major Licensing Deals
6.2 Co-development Agreements
6.2.1 Major Co-development Agreements

7 Appendix
7.1 All Pipeline Drugs by Phase
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 Phase I
7.1.4 Phase II
7.1.5 Phase III
7.2 Market Forecasts to 2021
7.2.1 Asia-Pacific
7.2.2 China
7.2.3 India
7.2.4 Japan
7.2.5 Australia
7.3 Market Definitions
7.4 Abbreviations
7.5 References
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Primary Research
7.6.4 Therapeutic Landscape
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Expert Panel Validation
7.8 Contact Us
7.9 Disclaimer
Table 1: Anti-hypertensive Therapeutics, Possible Co-morbidities
Table 2: Anti-hypertensive Therapeutics, Proposal for Outcome-Driven Reference Values for Ambulatory Blood Pressure Measurement (mmHg)
Table 3: Anti-hypertensive Therapeutics, Blood Pressure Classification in Adults (mmHg)
Table 4: Anti-hypertensive Therapeutics, Definitions of Hypertension by Office and Out-of-Office Blood Pressure Levels (mmHg)
Table 5: Anti-hypertensive Therapeutics, Prevalence of Hypertension
Table 6: Anti-hypertensive Therapeutics, Suggested Medications for Hypertensive Patients with Certain Medical Conditions
Table 7: Anti-hypertensive Therapeutics, Lifestyle Measures and Recommendations
Table 8: Anti-hypertensive Therapeutics, Compelling and Possible Contra-indications of Anti-hypertensive Drugs
Table 9: Anti-hypertensive Therapeutics, Preference of Drug in Specific Condition/Situation of Hypertensive Patients
Table 10: Anti-hypertensive Therapeutics, Global, All Pipeline Products, Discovery, 2015
Table 11: Anti-hypertensive Therapeutics, Global, All Pipeline Products, Preclinical, 2015
Table 12: Anti-hypertensive Therapeutics, Global, All Pipeline Products, Phase I, 2015
Table 13: Anti-hypertensive Therapeutics, Global, All Pipeline Products, Phase II, 2015
Table 14: Anti-hypertensive Therapeutics, Global, All Pipeline Products, Phase III, 2015
Table 15: Anti-hypertensive Therapeutics, Asia-Pacific, Market Forecast, 2014–2021
Table 16: Anti-hypertensive Therapeutics , China, Market Forecast, 2014–2021
Table 17: Anti-hypertensive Therapeutics , India, Market Forecast, 2014–2021
Table 18: Anti-hypertensive Therapeutics , Japan, Market Forecast, 2014–2021
Table 19: Anti-hypertensive Therapeutics , Australia, Market Forecast, 2014–2021
Table 20: Abbreviations
Figure 1: Anti-hypertensive Therapeutics, Physiological Mechanism of Renin Angiotensin Aldosterone System
Figure 2: Anti-hypertensive Therapeutics, Global, Prevalence Rate (%), 2007–2010
Figure 3: Anti-hypertensive Therapeutics, Treatment Algorithm of Hypertension
Figure 4: Anti-hypertensive Therapeutics, Influence of Drugs on the Renin Angiotensin Aldosterone System
Figure 5: Anti-hypertensive Therapeutics, Treatment Algorithm, 2014
Figure 6: Anti-hypertensive Therapeutics, Global, Comparative Safety and Efficacy of Marketed Products, 2015
Figure 7: Anti-hypertensive Therapeutics, Global, Pipeline by Stage of Development and Program Type, 2015
Figure 8: Anti-hypertensive Therapeutics, Global, Pipeline by Molecule Type and Stage of Development, 2015
Figure 9: Anti-hypertensive Therapeutics, Global, Pipeline by Mechanism of Action, 2015
Figure 10: Anti-hypertensive Therapeutics, Global, Clinical Trial Failure Rate (%), 2015
Figure 11: Anti-hypertensive Therapeutics, Global, Clinical Trial Size, 2015
Figure 12: Anti-hypertensive Therapeutics, Global, Clinical Trial Duration (months), 2015
Figure 13: Anti-hypertensive Therapeutics, Asia-Pacific, Treatment Use Patterns, Patients (million), 2014–2021
Figure 14: Anti-hypertensive Therapeutics, Asia-Pacific, Market Size ($bn), 2014–2021
Figure 15: Anti-hypertensive Therapeutics, Australia, Treatment Use Patterns, Patients (million), 2014–2021
Figure 16: Anti-hypertensive Therapeutics, Australia, Annual Cost of Therapy ($), 2014–2021
Figure 17: Anti-hypertensive Therapeutics, Australia, Market Size ($bn), 2014–2021
Figure 18: Anti-hypertensive Therapeutics, India, Treatment Use Patterns, Patients (million), 2014–2021
Figure 19: Anti-hypertensive Therapeutics, India, Annual Cost of Therapy ($), 2014–2021
Figure 20: Anti-hypertensive Therapeutics, India, Market Size ($bn), 2014–2021
Figure 21: Anti-hypertensive Therapeutics, China, Treatment Use Patterns, Patients (million), 2014–2021
Figure 22: Anti-hypertensive Therapeutics, China, Annual Cost of Therapy ($), 2014–2021
Figure 23: Anti-hypertensive Therapeutics, China, Market Size ($bn), 2014–2021
Figure 24: Anti-hypertensive Therapeutics, Japan, Treatment Use Patterns (million), 2014–2021
Figure 25: Anti-hypertensive Therapeutics, Japan, Annual Cost of Therapy ($), 2014–2021
Figure 26: Anti-hypertensive Therapeutics, Japan, Market Size ($bn), 2014–2021
Figure 27: Anti-hypertensive Therapeutics, Global, Licensing Deals by Region, Phase and Value, 2006– Q1 2015
Figure 28: Anti-hypertensive Therapeutics, Global, Licensing Deals by Phase and Mechanism of Action, 2006–Q1 2015
Figure 29: Anti-hypertensive Therapeutics, Global, Licensing Deals by Geography, 2006–Q1 2015
Figure 30: Anti-hypertensive Therapeutics, Global, Co-development Deals by Region, Value and Phase, 2006– Q1 2015
Figure 31: Anti-hypertensive Therapeutics, Global, Co-development Deals by Phase and Mechanism of Action, 2006–Q1 2015
Figure 32: Anti-hypertensive Therapeutics, Global, Co-development Deals by Geography, 2006–Q1 2015
Figure 33: GBI Research Market Forecasting Model (Example)